Difference between revisions of "Team:UofC Calgary/Human Practices"

For any new scientific creation, it is important to imagine how the project will impact existing political, economic, and societal frameworks. This is particularly important for projects that can have far-reaching consequences, such as ones involving cells in a therapeutic product, or products with novel applications such as space travel.

When designing our product, we had many questions of how we can optimize the design to best address the numerous political, manufacturing, economic, as well as end user experience aspects of our product throughout its lifecycle. In order to get answers to these questions, our human practices team did extensive research, as well as conducted numerous interviews with professionals working in related fields. See all the professionals that we have spoken to in order to improve our project design on our Human Practices Silver Medal page.

We've incorporated all of the comments we've obtained from professionals into the design of our product. See how all the feedback has informed our project design on our Human Practices Gold Medal page.

See our human practices highlights on our Integrated Human Practices page.

As part of integration of human practices into our project, we've also considered the process it would take for our drug to go from the lab bench to the market. To such ends, we decided to reach out to Dr. Agnes Klein, who is currently the Director of the Centre for Evaluation of Radiopharmaceuticals and Biotherapeutics at Health Canada. Details about our conversations can be found here.

During our conversation, Dr. Klein made aware to us that there are currently no specific regulations in Canada pertaining to the development and marketization of synbio products. Having specific regulations would be beneficial for both prevention of adverse events as well as streamline the process of synbio drug approval.

We decided to address this gap in current Canadian regulations by writing a policy brief.